BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
Torrent Pharmaceuticals Ltd.’s Ebita margin has consistently improved over the years backed by superior business mix, strong execution and operating leverage.
Ebitda margin improved approximately 400 basis points over FY18-FY20 and we expect it to improve further 350 basis points over FY20-FY23E driven by operating leverage and improving revenue mix.
We are positive on the long-term outlook considering growth improvement in India business with dominance of chronic segment, potential resolution of official action indicated status at two facilities in FY21, earning per share compound annual growth rate of 24.2% over FY20-FY23E and strengthening balance sheet with growing free cash flows.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR